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receptor-mediated, angiotensin II-independent
mechanisms
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Recent evidence suggesting a strong interplay between
components of the renin–angiotensin system and key
mediators of fibrosis led us to hypothesize that renin,
independent of its enzymatic action to enhance angiotensin
(Ang) II synthesis, directly increases production of the
fibrogenic cytokine transforming growth factor (TGF)-b.
Human or rat mesangial cells (MCs) were treated with human
recombinant renin (HrRenin) or rat recombinant renin
(RrRenin) and the effects on TGF-b1, plasminogen activator
inhibitor-type 1 (PAI-1), fibronectin (FN) and collagen 1
mRNA and protein were investigated. Blockade of the rat MC
renin receptor was achieved using siRNA. HrRenin or RrRenin,
at doses shown to be physiologically relevant, induced
marked dose- and time-dependent increases in TGF-b1.
These effects were not altered by adding an inhibitor of
renin’s enzymatic action (RO 42-5892), the Ang II receptor
antagonist losartan or the Ang-converting enzyme inhibitor
enalapril. RrRenin also induced PAI-1, FN and collagen 1
mRNA and PAI-1 and FN protein in a dose-dependent
manner. Neutralizing antibodies to TGF-b partially blocked
these effects. Supernatant and cell lysate Ang I and Ang II
levels were extremely low. MC angiotensinogen mRNA was
undetectable both with and without added renin. Targeting
of the rat renin receptor mRNA with siRNA blocked induction
of TGF-b1. We conclude that renin upregulates MC TGF-b1
through a receptor-mediated mechanism, independent of
Ang II generation or action. Renin-induced increases in
TGF-b1 in turn stimulate increases in PAI-1, FN and collagen I.
Thus, renin may contribute to renal fibrotic disease,
particularly when therapeutic Ang II blockade elevates
plasma renin.
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In the classical renin–angiotensin system, renin has been
considered to have no biological activity except to enzyma-
tically cleave angiotensinogen (ANG) to angiotensin (Ang) I.1
Although several cell membrane proteins have been shown to
bind renin, no functional effects of such binding have been
reported.2–4 Recently, a renin receptor was identified on
human mesangial cells (MCs).5,6 Binding of renin to this
receptor induced a hypertrophic effect and increased the
synthesis of plasminogen activator inhibitor-type 1 (PAI-1).5
This effect is not likely due to renin proteolytic activity
leading to Ang II generation, as an inhibitor of renin’s
enzymatic action had no effect. This receptor has been cloned
and is a 350-amino-acid protein with a single transmembrane
domain and no homology with any known membrane
protein.6 Binding to this protein is specific for renin and
prorenin. Very recently, a closely related renin receptor was
cloned from rats.7 Although there are no data on cellular
effects of the rat renin receptor, human receptor-bound renin
induces phosphorylation of serine and tyrosine residues,
associated with activation of mitogen-activated protein
kinases extracellular signal-regulated kinase (ERK) 1 and
ERK2. This action was not altered in the presence of either
an Ang-converting enzyme inhibitor (ACEi) or an Ang II
receptor antagonist (ARB), further confirming that the
receptor-mediated events are independent of Ang II genera-
tion or action. In addition, mice that lack Ang II or Ang II
receptor binding because of genetic deficiencies in ANG, ACE
or Ang II receptors have high renin levels and develop
vascular and glomerular sclerosis.8–10 Taken together, these
data suggest that renin may have specific, receptor-mediated
actions in addition to its role as an aspartyl protease.
In the hypertrophic juxtaglomerular apparatus (JGA) of a
hypertensive human, renin has been shown to colocalize with
the profibrotic cytokine transforming growth factor (TGF)-
b.11 Treatment of rats with ACEi further increases renin and
TGF-b in the JGA,12 suggesting that the production of renin
and TGF-b is coregulated there and that Ang II is not
mediating increases in TGF-b.12,13
Knowledge that renin and TGF-b may be coregulated in
the JGA, that renin upregulates PAI-1 synthesis through a
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receptor on MCs, that TGF-b is a potent stimulator of PAI-1
synthesis14–16 and that animals deficient in Ang II have high
renin levels and develop glomerulosclerosis8 led us to
hypothesize that renin may act through receptor-mediated,
Ang II-independent mechanisms to upregulate synthesis of
MC TGF-b and thereby contribute directly to renal fibrosis.
Investigation of this hypothesis is of great clinical relevance
because the most effective antifibrotic therapies currently
available are ACEis and ARBs and these agents markedly
elevate plasma renin levels. Human and animal data suggest
that, even at high doses, these drugs only slow down
progression to end-stage organ failure. The limited effective-
ness of these drugs may be due, in part, to the elevated renin
levels they induce and the Ang II-independent, profibrotic
actions of renin.
RESULTS
HrRenin effects on TGF-b1 production by human MCs
Human recombinant renin (HrRenin)-treated human MCs
showed progressive increases in TGF-b1 levels from the first
time point of 4 h up to 72 h, both in control and in renin-
treated cell culture supernatants (Figure 1a). Because the
difference in TGF-b production between renin-treated and
control cells became significant at 24 h (Po0.02), 24 h was
used for further experiments. A dose-dependent increase in
TGF-b1 was seen, with a four-fold increase at the highest
dose of 106 M HrRenin (Po0.01; Figure 1b). Treatment of
cells with RO 42-5892, which blocks human renin’s
enzymatic conversion of ANG to Ang I, the ACEi enalapril
or the ARB losartan had no effect on renin-induced increases
in TGF-b1 production (Figure 1c).
Production of rat renin
The recombinant prorenin elution profile revealed three
peaks containing prorenin (Figure 2). When prorenin
(B43 kDa) was digested by trypsin, it was cleaved to renin
(B34 kDa) (Figure 3a). The enzymatic activity of renin
increased more than 1000-fold after trypsin digestion (Figure
3b). There was no measurable renin activity in the control
buffer.
Plasma and glomerular renin concentrations in normal and
nephritic rats
Plasma renin activity and glomerular renin content did not
differ between control and nephritic rats (Table 1). Using the
assumption that plasma and glomerular renin have the same
specific activity (U/mol) as rat recombinant renin (RrRenin),
the physiological plasma renin concentration in control and
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Figure 1 | (a) Time course of TGF-b1 protein induction by HrRenin.
Control TGF-b1 production in the supernatant at 4 h was used as the
control value and is set at a value of 1. *Po0.02 vs control. (b) Dose
response of TGF-b1 production by HrRenin. *Po0.05 vs control.
(c) Effect of coincubation of renin with a blocker of renin’s enzymatic
action or Ang II blockers on TGF-b1 production. Panel b and c values
are expressed as fold-increases over the no-additive control.
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Figure 2 | (a) Purification of rat recombinant prorenin on a Ni2þ -
charged iminodiacetic acid-Sepharose resin. 35S-labeled rat
recombinant prorenin was applied to a Ni2þ -charged iminodiacetic
acid-Sepharose resin column (5 ml, HiTrap Chelating HP, Amersham
Biosciences AB, Uppsala, Sweden) in 20 mM imidazole buffer. The
bound material was eluted by a stepwise increase of imidazole to
50 mM, and a linear gradient of imidazole from 50 to 200 mM. The
dotted line indicates imidazole concentration. The continuous line
corresponds to purified protein. (b) Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis of pure rat
recombinant prorenin. Selected fractions of the three elution peaks
were subjected to SDS-PAGE. Fraction numbers 21 and 71, on either
side of the elution peaks, served as control. Bands were visualized by
Coomassie blue staining. Mr: molecular weight marker.
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diseased rats was estimated to be 1.0 1011 M (Table 1).
Glomerular renin concentration was about 100-fold greater
at 109 M. Enalapril treatment of nephritic rats increased
glomerular renin mRNA expression 13-fold (Figure 4).
Plasma and glomerular renin activities were increased 5.6-
and 8.9-fold, respectively, bringing the estimated glomerular
renin concentration in enalapril-treated, nephritic rats into
the 108 M range (Table 1). Therefore, renin concentrations
around 108 M were used in further experiments.
RrRenin effect on rat MCs TGF-b1
TGF-b1 mRNA expression was elevated significantly by
almost two-fold (Po0.05) at 1/2 h after renin treatment and
remained more than three-fold increased from 2 h to at least
8 h (Figure 5). Dose-dependent increases in TGF-b1 mRNA
were seen after 4 h (Po0.01; Figure 6a and b). That mRNA
increases resulted in protein increases is shown in Figure 6c
where TGF-b1 protein was increased 165% after 48 h.
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Figure 3 | (a) Processing of rat recombinant prorenin by
immobilized TPCK trypsin. Active renin was generated by
incubation of purified (His)6-prorenin with agarose-immobilized TPCK
trypsin (Pierce, Rockford, IL, USA) for 6 h at 371C. Trypsin was
removed by centrifugation and the (His)6-propeptide was removed
from the supernatant by Ni2þ affinity chromatography. Concentrated
prorenin and renin were applied to SDS-PAGE gels, stained and
photographed. (b) Renin activity of rat recombinant prorenin and
renin determined by an Ang I generation assay. Samples were
collected from prorenin, before and after trypsin digestion. The same
volume of phosphate-buffered saline was trypsin digested and used
to control for an effect of trypsin on renin activity. Renin activity was
determined as the ability of a sample to generate Ang I from
nephrectomized rat serum substrate (containing ANG).
Table 1 | Renin activity and concentration in normal and
nephritic rats and in RrRenin
Renin
activity
Renin
content (M)
Plasma
(ng Ang
I/ml/h)
Glomeruli
(ng Ang I/ml/
104 glom/h) Plasma Glomeruli
Normal control
(NC; N=6)
10.8471.85 11457143 1.00 1011 1.06 109
Disease control
(DC; N=6)
10.2570.99 11607212 0.95 1011 1.07 109
DC+enalapril
(N=6)
60.3172.55 10 2767328 5.58 1011 0.95 108
RrRenin 2.7 106 2.5 106
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Figure 4 | Effects of enalapril treatment on rat glomerular renin
mRNA expression in glomerulonephritis. A representative North-
ern blot is shown in (a) and presented graphically in (b). *Po0.001 vs
normal (N) or disease control (DC).
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Figure 5 | Time course of TGF-b1 mRNA induction by RrRenin.
Densitometric values are expressed relative to the no-additive, zero-
time control, which was set at unity. *P vs control o0.05.
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Figure 6 | Effect of RrRenin dose on TGF-b1 mRNA (a, b) and
protein production (c). TGF-b1 mRNA (b) and protein (c) values are
expressed relative to the no-additive control, which was set at unity.
*Po0.05 vs control. C: control.
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Effect of RrRenin on PAI-1 and extracellular matrix expres-
sion
Renin stimulated PAI-1 mRNA 9-fold at 1 h and 13-fold at
2 h (Po0.05). PAI-1 mRNA then declined to control levels by
6 h (Figure 7). PAI-1 mRNA increased in a dose-dependent
manner between 1010 and 108 M RrRenin, resulting in a
215% increase in protein after 48 h (Figure 8).
Treatment of cultures with the TGF-b-neutralizing anti-
body (Ab), 1D11, or control IgG for 2 or 4 h significantly, but
not completely, blocked the stimulation of PAI-1 mRNA
synthesis. 1D11 reduced RrRenin-induced increases in PAI-1
mRNA by 12% at 2 h and by 68% at 4 h (Figure 9).
Significant increases in fibronectin (FN) and type 1 collagen
mRNA were seen at two renin concentrations at 4 h (Po0.05;
Figure 10a–c). RrRenin significantly increased FN protein
production after 24 h of incubation, in a dose-dependent
manner (Figure 10d). Ab to TGF-b, but not control Ab,
significantly reduced production of FN by 39% (Figure 10e).
Evidence that renin effects are independent of Ang II
generation
Reports that MCs contain ANG mRNA at very low levels, and
renin, ACE and Ang II receptors suggest that these cells have
all the components necessary to synthesize Ang II.17,18 Thus,
it is important to rule out the possibility that renin effects on
TGF-b in vitro are mediated by increased Ang II production.
Two previous publications suggest that renin receptor
signaling and upregulation of PAI-1 are independent of
Ang II generation or action.5,7 We provide here seven
additional lines of evidence that renin’s effects on TGF-b
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Figure 7 | Time course of PAI-1 mRNA induction by RrRenin.
Densitometric values are expressed relative to the no-additive, zero-
time control, which was set at unity. *P vs control o0.05.
a
b d
c
RrRenin RrRenin
RrRenin (M) RrRenin (M)
18
15
12
9
6
3
0
Control Control
GAPDH
PAI-1
1.5 kb
3.1 kb 55 kDa 50 kDa
43 kDa
PA
I-1
 m
R
N
A 
ex
pr
es
sio
n
R
el
at
ive
 to
 c
on
tro
l
PA
I-1
 p
ro
du
ct
io
n
R
el
at
ive
 to
 c
on
tro
l
2.5
2.0
1.0
0.5
0.0
1.5∗
∗
∗
∗
10
−
10 M
10
−
8 M
10
−
10 M
10
−
9 M
10
−
8 M
Con
trol
Con
trol
Ma
rke
r
10−10 10−8 10−1010−9 10−8
Figure 8 | Effect of RrRenin dose on PAI-1 mRNA (a, b) and protein
production (c, d). PAI-1 mRNA (b) and protein (d) values are
expressed relative to the no-additive control, which was set at unity.
*Po0.05 vs control.
2 h 4 h
a c
db
PAI-1PAI-1
GAPDH GAPDH
3.1 kb
1.5 kb
2.0
1.5
1.0
0.5
2.5
3.0
3.5
0
C+IgG C+
1D11
PA
I-1
 m
R
N
A 
ex
pr
es
sio
n
R
el
at
ive
 to
 c
on
tro
l
∗
∗
Co
ntr
ol
+Ig
G Co
ntr
ol
+1
D1
1
Rr
Re
nin
+Ig
G RrR
en
in
+1
D1
1
Co
ntr
ol
+Ig
G Co
ntr
ol
+1
D1
1
Rr
Re
nin
+Ig
G RrR
en
in
+1
D1
1
2.0
1.5
1.0
0.5
2.5
3.0
3.5
0PA
I-1
 m
R
N
A 
ex
pr
es
sio
n
R
el
at
ive
 to
 c
on
tro
l
RrRenin
+1D11
RrRenin
+IgG
C+IgG C+
1D11
RrRenin
+1D11
RrRenin
+IgG
Figure 9 | Effect of neutralizing TGF-b Ab (5 lg/ml, 1D11) on
renin-induced increases in PAI-1 mRNA. (a, c) mRNA was analyzed
at 2 and 4 h incubations, respectively. (b, d) mRNA data are presented
graphically. Densitometric values are expressed relative to the
controlþ IgG value at each time point, which was set at unity.
*Po0.05 vs reninþ control Ab (IgG). C: control.
a
b
d
e
c
RrRenin
RrRenin
+IgG
RrRenin
+1D11
2.0
1.5
1.0
0.5
0
2.5
3.0
2.0
1.5
1.0
0.5
0
2.5
2.0
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
Control
+IgG
Control
+1D11
RrRenin (M)
Control 10−1110−10 10−9 10−810−12
FN-EDA+
Collagen I
GAPDH
8.0 kb
5.7 kb
4.7 kb
1.5 kb
Co
lla
ge
n 
I
m
R
N
A 
ex
pr
es
si
on
∗
∗
∗
∗
∗
∗∗
∗
∗∗
#
10
−
10  
M
10
−
8  M
Co
ntr
ol
FN
-E
DA
+
m
R
N
A 
ex
pr
es
sio
n
RrRenin (M)
Control 10−810−10
RrRenin (M)
Control 10−810−10
FN
 p
ro
du
ct
io
n
R
el
at
ive
 to
 c
on
tro
l
FN
 p
ro
du
ct
io
n
R
el
at
ive
 to
 c
on
tro
l
Figure 10 | (a–c) Effect of RrRenin dose on FN-EDAþ and collagen
I mRNA expression at 4 h. Densitometric values are expressed
relative to the no-additive control, which was set at unity. *P vs
control o0.05. **Po0.05 vs 1010 M renin. (d) Dose response of FN
protein production by RrRenin after 24 h incubation. FN protein
values are expressed relative to the no-additive control in (d) and to
the controlþ IgG value in (e), both of which were set at unity.
*Po0.05 vs control. (e) Effect of neutralizing TGF-b Ab (5 mg/ml,
1D11) on renin-induced increases in FN production. *Po0.05 vs
controlþ IgG, #Po0.05 vs RrReninþ IgG.
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are Ang II independent. (1) As previously published for PAI-
1,5 data presented in Figure 1c indicate that an inhibitor of
renin’s enzymatic action to convert ANG to Ang I had no
effect on renin-induced upregulation of TGF-b. This suggests
that renin does not act through increasing Ang II generation.
(2) ANG mRNA was undetectable in cultured rat MCs by
reverse transcriptase-polymerase chain reaction (RT-PCR)
even when 1000-fold the recommended amount of RNA
(1mg) was used (Figure 11a, left). A 3 mg portion of RNA
produced a very weak band after 40 cycles of PCR (data not
shown). In contrast, there is abundant ANG mRNA in rat
liver tissue (Figure 11a). That gels were loaded with equal
amounts of RNA is shown by the gel on the right of Figure
11a, where b-actin and ANG primers were used. (3) There
was no visible ANG mRNA signal in MCs treated with
0–107 M RrRenin or 0–106 M Ang II for 4 h (data not
shown). Additional amplification of the first RT-PCR
products did not alter the results, further confirming that
MC ANG mRNA is very low. Thus, renin does not induce
MC production of ANG, which might be converted to Ang II.
(4) Consistent with ANG mRNA levels, Ang I levels were
below the detectable range of pg/ml in both cultured
supernatant and cell lysate, indicating that a reservoir of
Ang I is not available to convert to Ang II (data not shown).
(5) Ang II levels in culture supernatants were in the 1011 M
range, much lower than physiological levels,19 below the level
of significant induction of TGF-b reported at 108 M Ang II20
and were not increased by renin treatment (data not shown).
(6) Ang II was undetectable in cell lysates and was not
increased by renin treatment (data not shown). (7) Treatment
of cells with enalaprilate or losartan had no effect on TGF-b1
mRNA levels either in the absence or presence of RrRenin,
indicating that blocking the action of any Ang II present does
not alter renin’s effect (Figure 11b–e). These results indicate
that the limited amount of ANG mRNA present in MCs fails
to produce significant Ang II either in untreated or renin-
treated MCs.
Role of MC renin receptor in renin-induced increases in
TGF-b1
As a first step to determining whether renin upregulation of
TGF-b1 is renin receptor-mediated, we determined by RT-
PCR that renin/prorenin receptor mRNA is abundant in rat
MCs (data not shown). Then, transfection of a Stealtht
siRNA molecule that targets the renin receptor was shown to
induce a dose-dependent decrease in receptor mRNA after
48 h (Figure 12a) and a time-dependent, 75% reduction in
receptor mRNA at 72 h (Figure 12b). Treatment of cells with
Lipofectaminet 2000 or Opti-MEM medium alone did not
affect renin receptor mRNA expression. Rat MCs transfected
for 72 h with 500 pmol Stealtht siRNA molecule had
undetectable renin receptor mRNA and showed significantly
reduced induction of TGF-b1 mRNA with RrRenin treatment
(Figure 13), indicating that the MC renin receptor mediates
renin-induced increases in TGF-b1 expression.
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with 1 lg RNA and ANG primers alone (left) or ANG plus b-actin
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DISCUSSION
We have shown here that HrRenin induces a dose-dependent
and marked increase in TGF-b1. To more thoroughly explore
this finding, it was necessary to produce RrRenin. The
assessment of human renin function in rats is impossible
because the species specificity of the renin–ANG reaction
makes the reaction rate of human renin with rat ANG
extremely slow21 and because human ANG is cleaved to Ang I
by human but not by rat renin.22 We then showed that
RrRenin increases TGF-b1 mRNA and protein at con-
centrations shown to be physiologically relevant by in vivo
measurement of renin levels in enalapril-treated, nephritic
rats. These effects extend to increased synthesis of PAI-1
and fibrotic extracellular matrix (ECM) components FN
and collagen I, and are partially mediated by TGF-b. That
the renin-induced increases in PAI-1 mRNA and FN protein
were only blocked by 68 and 39%, respectively, with
excess TGF-b Ab indicates that TGF-b-independent pathways
are responsible for part of the profibrotic action of
renin. siRNA targeting of the rat renin receptor com-
pletely blocked the renin-induced increase in TGF-b1
expression, indicating that this action is clearly renin receptor
dependent.
Considerable evidence presented here supports the idea
that these renin effects are independent of Ang II generation
or action. In addition, it is important to note that in vivo
data consistent with an Ang II-independent profibrotic
effect of renin exist in the literature. Both ANG and double
Ang II receptor Type 1A and 1B knockout mice show
increased renal renin staining, which is associated with
increased TGF-b staining and sclerosis.8,9 The data presented
here provide a potential mechanism for the fibrosis observed
in these animals.
Perhaps the most important and clinically relevant finding
in this study is that renin acts through Ang II-independent
mechanisms to promote fibrosis by inducing overexpression
of TGF-b1. Ang II, the major effector molecule of the
renin–angiotensin system, has been strongly implicated in
renal fibrosis.15,23 Numerous experimental studies, using
pharmacological or genetic means to manipulate Ang II
action, as well as clinical studies, have shown that Ang II
blockade reduces renal injury and fibrosis in part by reducing
TGF-b.24,25 Ang II blockade is the greatest therapeutic
breakthrough in renal fibrosis in the past two decades.
However, Ang II blockade does not normalize TGF-b levels,
and disease progression is slowed, but not halted. Indeed,
studies from our laboratory using superpharmacological
doses of ACEi or ARB alone, or in combination, suggest that
the maximal reduction in disease markers with Ang II
blockade is about 50% in experimental nephritis.13,26,27 These
findings are entirely consistent with the limitations of Ang II
blockade to halt renal fibrosis in human clinical medicine.
The therapeutic limitations of Ang II blockade strongly
suggest that other molecules contribute to TGF-b over-
expression. Ang II inhibits both renin secretion and renin
synthesis through the Ang II type 1 receptor in the renal
JGA.28–30 Conversely, blockade of Ang II with either ACEi or
ARB increases plasma and renal renin expression by 5- to 10-
fold in both human patients and in experimental mod-
els,29,31–35 data that are confirmed in Table 1 and Figure 4.
Our results raise the important possibility that the elevated
renin seen with Ang II blockade may, independent of Ang II,
contribute to overproduction of TGF-b1, PAI-1 and fibrotic
matrix components and thereby contribute to disease
progression.
CONCLUSION
The present study demonstrates that human and rat renin
rapidly and dramatically upregulate TGF-b1 production by
MCs through a receptor-mediated mechanism, independent
of Ang II generation. Renin-induced increases in TGF-b1 in
turn stimulate increases in PAI-1, FN and collagen I. While
further in vivo work is needed to determine whether the in
vitro renin effects seen here play a role in fibrotic renal
disease, the data presented raise the intriguing possibility that
the high plasma renin levels induced by therapeutic Ang II
blockade may, in fact, contribute to the limited effectiveness
of this therapy.
MATERIALS AND METHODS
Reagents
HrRenin and RO 42-5892, a blocker of renin’s enzymatic action to
convert ANG to Ang I, were kindly provided by Hoffmann-Laroche.
Unless otherwise indicated, other reagents were purchased from
Sigma (St Louis, MO, USA).
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Figure 13 | Effect of Stealtht siRNA on renin-induced TGF-b1
mRNA expression and rat renin receptor mRNA expression. Renin
receptor and TGF-b1 mRNA levels were determined by Northern blot
and standardized for densitometric analysis to GAPDH mRNA levels.
The rat renin receptor cDNA was synthesized by RT-PCR and purified
using the NucleoSpins Extraction kit (Clontech Laboratories Inc.).
Densitometric values are expressed relative to the Lipofectaminet
2000 (Lipo)-transfected, no renin added control, which was set at
unity. *Po0.05 vs control, #Po0.05 vs Stealtht siRNA-transfected
cells plus renin.
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Human and rat MC culture
Human fetal MCs were purchased from Clonetics (San Diego, CA,
USA). Rat MCs were derived and maintained as described
previously20 and used between passages 4 and 7. Cells were seeded
in six-well plates, grown to subconfluency and placed in serum-free
medium for 48 h prior to experimental studies. Cells were treated
with HrRenin with or without addition of RO 42-892, enlaprilate
(the active form of enalapril) or losartan. TGF-b1 production was
measured on culture supernatants as described.36
Production of RrRrenin from eukaryotic cells
A full-length cDNA-encoding rat prorenin was obtained by RT-PCR
and cloned into the vaccinia virus expression vector pT-cam1.37
Total cytoplasmic RNA was extracted from isolated rat glomeruli
from salt-depleted rats. The first-strand cDNA was synthesized using
the downstream primer Ren-2 (50-CAGGAACTC-
GAGCTTTGGCTTGGCCTAAAA-30). A cDNA spanning the full-
length prorenin (devoid of the endogenous signal sequence) was
PCR amplified using the upstream primer Ren-1 (50-
TCTTGTCAATTGAGTCTCCCGACAGACACAG-30). An MfeI site
was introduced at the 50 end and an XhoI site at the 30 end by site-
specific changes in oligonucleotide primers. The PCR product was
digested with MfeI and XhoI and ligated into the EcoRl/XhoI site of
pT-cam1 to yield pT-Prorenin. PT-Prorenin encodes the rat
prorenin as a fusion protein linked to the insulin signal sequence
and a polyhistidine (6His) sequence under the control of the
bacteriophage T7 promoter. M13 sequencing spanning the entire
cDNA ensured that there were no errors introduced by either PCR
or ligation artifacts. In vitro cell-free translation in a rabbit
reticulocyte lysate system (Promega Corporation, Madison, WI,
USA) generated a protein product of the predicted size (B43 kDa).
PT-Prorenin was used to generate a recombinant vaccinia virus
via homologous recombination between flanking thymidine kinase
sequences in pT-prorenin and wild-type vaccinia virus, as described
previously.38 The recombinant virus, vProrenin, was used to
overexpress secreted (His)6-prorenin in mammalian cells (HT-
1080 from ATCC, Manassas, VA, USA). Prorenin was purified by
metal chelating affinity chromatography (HiTrap Chelating HP,
Amersham Biosciences AB, Uppsala, Sweden). G50 columns (20 ml)
were run to equilibrate prorenin in phosphate-buffered saline.
Activated renin was generated by incubation of purified prorenin
with agarose-immobilized TPCK trypsin (Pierce, Rockford, IL,
USA). Renin activity was determined as described previously.39 Ang
I was quantitated using a commercially available RIA kit (NEN Life
Science Products Inc., Boston, MA, USA).
Renin content and activity
Renin content and activity were determined in glomeruli and
plasma from normal, nephritic and nephritic rats treated with high-
dose enalapril (200 mg/l drinking water26). Anti-thy-1 glomerulone-
phritis was induced as described.36 Animal housing and care were in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals, NIH Publication No. 85-23, 1985. The Institutional
Animal Care and Use Committee approved the protocol. Rats were
killed and blood was collected into 5% ethylenediaminetetraacetic
acid on day 6. Plasma was separated by centrifugation, snap-frozen
and stored at 701C. Glomeruli isolated by sieving40 were
resuspended at 1 104 glomeruli/ml in RIPA buffer (50 mM Tris/
HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate) containing 1 tablet/5 ml protease inhibitor
mix (Complete, Mini; Roche Diagnostics Corporation, Indianapolis,
IN, USA), subjected to two 15-s sonications, each followed by a 15-s
cool down and centrifuged at 400 g for 10 min at 41C. The
supernatant was stored at 701C. Total RNA was extracted
immediately from freshly isolated glomeruli as described below.
RNA of each group was pooled. Rat renin cDNA was obtained as
described above.
RrRenin actions on rat MCs
Cells were treated with RrRenin at the indicated doses and times.
Cells were then harvested for determination of RNA and protein
levels of TGF-b1, PAI-1, FN and collagen I. To assess whether
secreted TGF-b protein mediates the effects of RrRenin on PAI-1
and ECM protein expression, RrRenin-treated MCs were coin-
cubated with excess panspecific TGF-b Ab, 1D11 (R&D Systems
Inc., Minneapolis, MN, USA) or control IgG (5mg/ml).
Measurement of FN and TGF-b1 in cell lysate
Cells were lysed in 1 mM PMSF, 1% NP-40, 1 mM sodium
orthovanadate, 10 mM sodium fluoride, 5 mg/ml leupeptin, 5 mg/ml
pepstatin-A, 5 mg/ml aprotinin and 40 mM Tris-HCl, pH 7.4. Protein
concentration was determined using the BCA protein assay kit
(Pierce, Rockford, IL, USA). TGF-b1 and FN were measured as
described previously.36,41
PAI-1 Western blot analysis
MC culture supernatant (40 ml) was centrifuged and boiled for 5 min
after addition of 4 Laemmli buffer. The blots were processed and
quantitated as described.42
RNA preparation and Northern blot analysis
Total cellular RNA was isolated as described previously.36
Probes were labeled with 32P using the Strip-EZ Labeling kit
(Ambion) and hybridized overnight in Ultrhyb hybridization
buffer (Ambion). After washing, blots were exposed to films
that were scanned and analyzed by densitometry. Three blots
per probe were performed. Changes in mRNA levels were
determined by first correcting the densitometry intensity of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each
sample. For comparison, this ratio was set at unity for normal
control samples and other lanes on the same gel were expressed as
fold-increase over this value.
Ang II independence of renin-induced increases in TGF-b1
RT-PCR of rat ANG mRNA. Total RNA was isolated from rat
MCs treated with 0–107 M RrRenin or 0–106 M Ang II for 4 h, or
liver tissue (as a positive control).36 RT-PCR was performed
in a single reaction tube using the Superscript TM One-Step
RT-PCR with Platinum Taq System (Nitrogen Life Technologies
Inc., Gaithersburg, MD, USA). cDNA was synthesized for 30 min
at 501C, denatured for 2 min at 941C and amplified through
40 amplification cycles.43 To further identify ANG mRNA
expression by MCs, 2 ml of the first round of RT-PCR products
was used for a second round of PCR amplification with Taq
DNA polymerase (Nitrogen Life Technologies Inc., Gaithersburg,
MD, USA). Primer sequences were obtained from reported
data.43 RT-PCR efficiency was monitored by b-actin cDNA
amplification.
Effect of Ang II blockade on TGF-b1 mRNA and Ang I and Ang
II levels. MCs were exposed to RrRenin with or without
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enalaprilate or losartan for 4 h followed by measurement of TGF-b1
and GAPDH mRNA and cellular Ang I and Ang II. Ang I and Ang II
were also measured in culture supernatant. Ang I was measured as
above and Ang II levels were determined using a commercially
available competitive enzyme immunoassay kit (Division of
BACHEM, Peninsula Laboratories Inc., San Carlos, CA, USA).
Effect of silencing rat renin receptor pathway on renin-
induced increases in TGF-b1 mRNA expression
Using the newly published renin/prorenin receptor cDNA sequence
(GenBank accession number AB188298)6 and employing RNA
interference to decrease receptor expression, we asked whether the
effects of RrRenin to upregulate TGF-b1 were mediated by this
receptor.
Construction of rat renin/prorenin receptor Stealtht siRNA.
Stealtht RNA oligonucleotides are 25-base-pair double-stranded
RNA oligonucleotides with proprietary chemical modification that
provides decreased nonspecific stress responses for clearer results,
high potency for more powerful reduction of gene expression and
improved stability.44–46 The sequences of Stealtht siRNA were
designed using BLOCK-iTt RNAI Designer (Invitrogen Life
Technologies Inc., Gaithersburg, MD, USA), to target bp 595–619
of the rat renin/prorenin receptor molecule (sense strand: 50-CCU
CAA UUC UCU GAG UAG GAA UAA U-30; antisense strand: 30-
GGA GUU AAG AGA CUC AUC CUU AUU A-50). These Stealtht
RNA oligonucleotides were synthesized by Invitrogen Life Technol-
ogies Inc. (Gaithersburg, MD, USA).
Determination of rat renin/prorenin receptor mRNA expres-
sion. Total RNA was isolated using Trizolt reagent. RT-PCR
was carried out as described above. cDNA was amplified through
36 amplification cycles (941C for 15 s, 551C for 30 s, 721C
for 60 s), followed by a final extension for 7 min at 721C in a
DNA thermal cycler. RT-PCR efficiency was monitored by b-actin
cDNA amplification. Primers for rat renin/prorenin receptor
(forward primer: 50-CAC ATT GCG TCA GCT CCG TAA-30,
complementary to nucleotides 535–556; reverse primer: 50-CTC
ACC AGG GAT GTG TCG AAT-30, complementary to nucleotides
892–913; PCR product size 378 bp) and b-actin (forward primer:
50-ATC GTG GGC CGC CCT AGG CAC C-30, complementary
to nucleotides 100–121; reverse primer: 50-CTC TTT AAT GTC
ACG CAC GAT TTC-30, complementary to nucleotides 619–642;
PCR product size 542 bp) were constructed using Primer 3
Software. Amplified PCR product was confirmed on a 1.5%
agarose gel and a rough quantification was made with a gel
documentation program (Bio-Rad Corporation Inc., Hercules,
CA, USA).
Stealtht RNA interference. Before transfection, rat MCs were
maintained in 2.5% fetal calf serum medium and then transfected
with Lipofectaminet 2000 (Invitrogen Life Technologies Inc.,
Gaithersburg, MD, USA) and Stealtht siRNA according to the
manufacturer’s instructions. To test the effect of Stealtht siRNA on
renin-induced TGF-b1 mRNA expression, cells were treated with
RrRenin for 3 h for analysis of RNA after renin receptor depletion.
Statistical analysis
Results are presented as mean7s.d. A value of Po0.05 was
considered statistically significant (Student’s t-test). Duplicate wells
were analyzed for each experiment, and each experiment was
performed independently at least three times.
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